<DOC>
	<DOCNO>NCT01687699</DOCNO>
	<brief_summary>Aldosterone receptor blocker reduce cardiac-related morbidity mortality . Recently , demonstrate long-term low-dose spironolactone clinically safe many hemodialysis ( HD ) patient . In present study , ass whether low-dose spironolactone treatment reduces high incidence cardio- cerebrovascular ( CCV ) morbidity mortality HD patient . The investigator ' hypothesis aldosterone receptor blockade spironolactone reduces risk CCV morbidity death among HD patient .</brief_summary>
	<brief_title>Effects Spironolactone Cardio- Cerebrovascular Morbidity Mortality Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Hemodialysis patient undergo 4hourlong HD thrice week least 2 year With average serum potassium level ( immediately dialysis first day week ) &lt; 6.5 mEq/l previous 2 month With 24hour urine output &lt; 500 ml A history noncompliance Unstable vascular access Hypotension Hepatic failure Active cancer Any lifethreatening disease ESRD</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>cardiovascular event</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>spironolactone</keyword>
</DOC>